A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04464239
- Locations
- 🇺🇸
PPD Phase I unit, Austin, Texas, United States
First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03919409
- Locations
- 🇺🇸
PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale, California, United States
Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03746067
- Locations
- 🇺🇸
PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale, California, United States
Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03742791
- Locations
- 🇺🇸
PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale, California, United States
Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03141658
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: TS-121 10 mgDrug: TS-121 50 mgDrug: Placebo
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03093025
- Locations
- 🇺🇸
MCB Clinical Research Centers, Colorado Springs, Colorado, United States
🇺🇸Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸PAREXEL Early Phase Clinical Unit, Glendale, California, United States
Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02448212
- Locations
- 🇺🇸
Yale University PET Center, New Haven, Connecticut, United States
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2011-12-01
- Lead Sponsor
- Taisho Pharmaceutical R&D Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT00914186
- Locations
- 🇺🇸
UCSD, La Jolla, California, United States
🇺🇸J & S Studies, College Station, Texas, United States
🇺🇸Wake Forest University, Winston-Salem, North Carolina, United States